2. Academic Validation
  3. Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells

Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells

  • Cell Commun Signal. 2021 Sep 25;19(1):97. doi: 10.1186/s12964-021-00743-w.
Arindam Mondal 1,  Rachel NeMoyer 1,  Mehul Vora 2,  Logan Napoli 3,  Zoya Syed 3,  Elaine Langenfeld 1,  Dongxuan Jia 1,  Youyi Peng 4,  John Gilleran 5,  Jacques Roberge 5,  Christopher Rongo 2,  Salma K Jabbour 6,  John Langenfeld 7
Affiliations

Affiliations

  • 1 Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08903, USA.
  • 2 Department of Genetics, Rutgers University, Piscataway, NJ, 08854, USA.
  • 3 Rutgers University, Piscataway, NJ, 08854, USA.
  • 4 Biomedical Informatics Shared Resources, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08903, USA.
  • 5 Molecular Design and Synthesis, Rutgers University, Piscataway, NJ, 08854, USA.
  • 6 Department of Radiation Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903, USA.
  • 7 Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08903, USA. langenje@cinj.rutgers.edu.
PMID: 34563224 DOI: 10.1186/s12964-021-00743-w
Abstract

Background: Recent studies have shown that bone morphogenetic protein receptor 2 (BMPR2) regulates cell survival signaling events in Cancer cells independent of the BMP type 1 receptor (BMPR1) or the Smad-1/5 transcription factor. Mutations in BMPR2 trafficking proteins leads to overactive BMP signaling, which leads to neurological diseases caused by BMPR2 stabilization of the microtubules. It is not known whether BMPR2 regulates the microtubules in Cancer cells and what effect this has on cell survival. It is also not known whether alterations in BMPR2 trafficking effects activity and response to BMPR2 inhibitors.

Methods: We utilized BMPR2 siRNA and the BMP Receptor inhibitors JL5 and Ym155, which decrease BMPR2 signaling and cause its mislocalization to the cytoplasm. Using the JL5 resistant MDA-MD-468 cell line and sensitive lung Cancer cell lines, we examined the effects of BMPR2 inhibition on BMPR2 mislocalization to the cytoplasm, microtubule destabilization, lysosome activation and cell survival.

Results: We show that the inhibition of BMPR2 destabilizes the microtubules. Destabilization of the microtubules leads to the activation of the lysosomes. Activated lysosomes further decreases BMPR2 signaling by causing it to mislocalizated to the cytoplasm and/or lysosome for degradation. Inhibition of the lysosomes with chloroquine attenuates BMPR2 trafficking to the lysosome and cell death induced by BMPR2 inhibitors. Furthermore, in MDA-MD-468 cells that are resistant to JL5 induced cell death, BMPR2 was predominately located in the cytoplasm. BMPR2 failed to localize to the cytoplasm and/or lysosome following treatment with JL5 and did not destabilize the microtubules or activate the lysosomes.

Conclusions: These studies reveal that the inhibition of BMPR2 destabilizes the microtubules promoting cell death of Cancer cells that involves the activation of the lysosomes. Resistance to small molecules targeting BMPR2 may occur if the BMPR2 is localized predominantly to the cytoplasm and/or fails to localize to the lysosome for degradation. Video Abstract.

Figures
Products